Arvinas, Inc. (NASDAQ:ARVN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Arvinas, Inc. (NASDAQ:ARVN) has been given an average recommendation of “Moderate Buy” by the sixteen ratings firms that are covering the stock, MarketBeat Ratings reports. Five investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $34.33.

A number of equities analysts have recently commented on the company. BMO Capital Markets set a $20.00 price target on Arvinas and gave the stock an “outperform” rating in a report on Wednesday, March 12th. Wells Fargo & Company set a $26.00 target price on shares of Arvinas and gave the stock an “overweight” rating in a report on Wednesday, March 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arvinas in a research report on Friday, February 7th. Morgan Stanley dropped their price target on Arvinas from $48.00 to $12.00 and set an “equal weight” rating for the company in a research note on Thursday, March 13th. Finally, Citigroup lowered their target price on Arvinas from $28.00 to $19.00 and set a “neutral” rating for the company in a report on Friday, March 7th.

Arvinas Stock Up 2.7 %

ARVN stock opened at $9.62 on Thursday. The company’s 50-day moving average price is $10.05 and its two-hundred day moving average price is $17.76. The firm has a market cap of $661.59 million, a P/E ratio of -3.47 and a beta of 2.30. Arvinas has a 12 month low of $5.94 and a 12 month high of $37.38.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same period in the previous year, the business earned ($2.53) EPS. Equities analysts predict that Arvinas will post -3.81 EPS for the current year.

Insider Buying and Selling

In other Arvinas news, insider Ian Taylor sold 9,020 shares of Arvinas stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $16.71, for a total value of $150,724.20. Following the completion of the sale, the insider now directly owns 159,121 shares in the company, valued at approximately $2,658,911.91. The trade was a 5.36 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Noah Berkowitz sold 8,658 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.59, for a total value of $74,372.22. Following the completion of the transaction, the insider now directly owns 110,023 shares in the company, valued at approximately $945,097.57. This trade represents a 7.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 50,230 shares of company stock valued at $769,402 over the last quarter. Insiders own 5.23% of the company’s stock.

Institutional Trading of Arvinas

Hedge funds have recently modified their holdings of the stock. GF Fund Management CO. LTD. bought a new position in Arvinas during the fourth quarter worth $28,000. KBC Group NV boosted its position in shares of Arvinas by 77.0% during the 4th quarter. KBC Group NV now owns 2,885 shares of the company’s stock worth $55,000 after purchasing an additional 1,255 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Arvinas by 11,283.8% in the 1st quarter. GAMMA Investing LLC now owns 4,212 shares of the company’s stock valued at $300,000 after buying an additional 4,175 shares during the period. KLP Kapitalforvaltning AS bought a new stake in Arvinas in the 4th quarter valued at about $171,000. Finally, Allspring Global Investments Holdings LLC acquired a new position in Arvinas during the 1st quarter worth approximately $80,000. Institutional investors own 95.19% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.